{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:53:31Z","timestamp":1791194011320,"version":"4.1.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>In the 2008 World Health Organization classification, cases of acute myeloid leukemia (AML) and myelodysplastic syndrome that arise after chemotherapy or radiation therapy for a primary neoplasm are considered together as therapy-related myeloid neoplasms (TR-MNs). This concept, however, is not universally accepted since there are confounding variables in attributing myeloid neoplasms to earlier therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Cases in session 6 of the 2013 Workshop of the Society for Hematopathology\/European Association for Haematopathology illustrated myeloid neoplasms thought likely to be TR-MNs, and discussed the differences and biologic similarities with de novo myeloid neoplasms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We reviewed data showing that diagnosis of TR-MN alters patient outcome only in specific subsets. The session also included examples of therapy-related AML with recurrent genetic abnormalities, such as t(15;17), inv(16), and t(8;21), and reports were highlighted showing that patients with these neoplasms have clinical outcomes similar to patients with their de novo counterparts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The study of TR-MNs will likely provide insight into the pathogenesis of de novo myeloid disease and may explain why some patients with cancer develop TR-MN and evidently have a higher genetic susceptibility, whereas most patients treated with the same agents do not. These studies will also result in critical reappraisal of current concepts related to TR-MNs.<\/jats:p><\/jats:sec>","DOI":"10.1309\/ajcpu1jo2lytwuav","type":"journal-article","created":{"date-parts":[[2015,7,16]],"date-time":"2015-07-16T12:48:53Z","timestamp":1437050933000},"page":"207-218","source":"Crossref","is-referenced-by-count":27,"title":["Therapy-Related Myeloid Neoplasms"],"prefix":"10.1093","volume":"144","author":[{"given":"Carlos E.","family":"Bueso-Ramos","sequence":"first","affiliation":[{"name":"Division of Pathology and Laboratory Medicine, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"additional","affiliation":[{"name":"Division of Pathology and Laboratory Medicine, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Routbort","sequence":"additional","affiliation":[{"name":"Division of Pathology and Laboratory Medicine, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[{"name":"The Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,8,1]]},"reference":[{"key":"2021050509375829000_b1-1440207","volume-title":"WHO Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"2021050509375829000_b2-1440207","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood-2012-08-448068","article-title":"Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975\u20132008","volume":"121","author":"Morton","year":"2013","journal-title":"Blood"},{"key":"2021050509375829000_b3-1440207","first-page":"1","article-title":"Myeloid neoplasms after breast cancer: \u201ctherapy-related\u201d not an independent poor prognostic factor","volume":"3","author":"Chen","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"2021050509375829000_b4-1440207","first-page":"261","article-title":"Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia","volume":"14","author":"Pemmaraju","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2021050509375829000_b5-1440207","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1038\/bcj.2013.19","article-title":"Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics","volume":"3","author":"Razavi","year":"2013","journal-title":"Blood Cancer J"},{"key":"2021050509375829000_b6-1440207","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.leukres.2013.12.023","article-title":"Therapy-related AML: a slip of the lip can sink a ship","volume":"38","author":"Gale","year":"2014","journal-title":"Leuk Res"},{"key":"2021050509375829000_b7-1440207","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.leukres.2014.08.002","article-title":"Why is there so much therapy-related AML and MDS and so little therapy-related CML?","volume":"38","author":"Gale","year":"2014","journal-title":"Leuk Res"},{"key":"2021050509375829000_b8-1440207","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.leukres.2012.09.008","article-title":"Therapy-related acute myeloid leukemia with favorable cytogenetics: still favorable?","volume":"36","author":"Aldoss","year":"2012","journal-title":"Leuk Res"},{"key":"2021050509375829000_b9-1440207","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.2004.99.301","article-title":"Prognosis in therapy-related acute myeloid leukemia and impact of karyotype","volume":"22","author":"Kern","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021050509375829000_b10-1440207","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/sj.leu.2403187","article-title":"Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML","volume":"18","author":"Schoch","year":"2004","journal-title":"Leukemia"},{"key":"2021050509375829000_b11-1440207","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","article-title":"Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series","volume":"102","author":"Smith","year":"2003","journal-title":"Blood"},{"key":"2021050509375829000_b12-1440207","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/leu.2013.191","article-title":"Application of the International Prognostic Scoring System\u2013Revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia","volume":"28","author":"Ok","year":"2014","journal-title":"Leukemia"},{"key":"2021050509375829000_b13-1440207","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3324\/haematol.2012.076729","article-title":"Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia","volume":"98","author":"Shih","year":"2013","journal-title":"Haematologica"},{"key":"2021050509375829000_b14-1440207","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"The role of early TP53 mutations of the evolution of therapy-related acute myeloid leukemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"key":"2021050509375829000_b15-1440207","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.leukres.2014.12.006","article-title":"Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases","volume":"39","author":"Ok","year":"2015","journal-title":"Leuk Res"},{"key":"2021050509375829000_b16-1440207","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood.V120.21.784.784","article-title":"Whole genome sequencing of therapy-related acute myeloid leukemia [abstract]","volume":"120","author":"Ramsingh","year":"2012","journal-title":"Blood"},{"key":"2021050509375829000_b17-1440207","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3324\/haematol.2011.040840","article-title":"TET2 mutations in secondary acute myeloid leukemias: a French retrospective study","volume":"96","author":"Kosmider","year":"2011","journal-title":"Haematologica"},{"key":"2021050509375829000_b18-1440207","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2141.2010.08404.x","article-title":"Evaluation of mutations in the isocitrate dehydrogenase genes in therapy-related and secondary acute myeloid leukaemia identifies a patient with clonal evolution to IDH2 R172K homozygosity due to uniparental disomy","volume":"152","author":"Pichler","year":"2011","journal-title":"Br J Haematol"},{"key":"2021050509375829000_b19-1440207","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/leu.2012.347","article-title":"IDH1 and IDH2 mutations in therapy-related myelodysplastic syndrome and acute myeloid leukemia are associated with a normal karyotype and with der(1;7)(q10;p10)","volume":"27","author":"Westman","year":"2013","journal-title":"Leukemia"},{"key":"2021050509375829000_b20-1440207","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ng.2696","article-title":"Somatic SETBP1 mutations in myeloid malignancies","volume":"45","author":"Makishima","year":"2013","journal-title":"Nat Genet"},{"key":"2021050509375829000_b21-1440207","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.3324\/haematol.2014.108159","article-title":"SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms","volume":"99","author":"Fabiani","year":"2014","journal-title":"Haematologica"},{"key":"2021050509375829000_b22-1440207","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/leu.2012.267","article-title":"Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases","volume":"27","author":"Voso","year":"2013","journal-title":"Leukemia"},{"key":"2021050509375829000_b23-1440207","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.clml.2014.03.001","article-title":"A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia","volume":"14","author":"Quintas-Cardama","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2021050509375829000_b24-1440207","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ajh.23605","article-title":"Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia","volume":"89","author":"Ornstein","year":"2014","journal-title":"Am J Hematol"},{"key":"2021050509375829000_b25-1440207","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1182\/blood.V94.2.803","article-title":"Prevalence of the inactivating 609C\u2192T polymorphism in the NAD(P) H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia","volume":"94","author":"Larson","year":"1999","journal-title":"Blood"},{"key":"2021050509375829000_b26-1440207","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/jmedgenet-2011-100674","article-title":"Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms","volume":"49","author":"Schulz","year":"2012","journal-title":"J Med Genet"},{"key":"2021050509375829000_b27-1440207","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.2011.473","article-title":"Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML","volume":"305","author":"Link","year":"2011","journal-title":"JAMA"},{"key":"2021050509375829000_b28-1440207","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1080\/10428190701769657","article-title":"Influence of DNA damage and repair upon the risk of treatment related leukemia","volume":"49","author":"Guillem","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"2021050509375829000_b29-1440207","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1158\/1078-0432.CCR-03-0372","article-title":"Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia","volume":"10","author":"Seedhouse","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2021050509375829000_b30-1440207","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/leu.2013.368","article-title":"The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia","volume":"28","author":"Jacoby","year":"2014","journal-title":"Leukemia"},{"key":"2021050509375829000_b31-1440207","doi-asserted-by":"crossref","first-page":"e2011032","DOI":"10.4084\/mjhid.2011.032","article-title":"Prognosis and therapy when acute promyelocytic leukemia and other \u201cgood risk\u201d acute myeloid leukemias occur as a therapy-related myeloid neoplasm","volume":"3","author":"Larson","year":"2011","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2021050509375829000_b32-1440207","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.leukres.2011.10.015","article-title":"Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia","volume":"36","author":"Ottone","year":"2012","journal-title":"Leuk Res"},{"key":"2021050509375829000_b33-1440207","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"key":"2021050509375829000_b34-1440207","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1182\/blood-2013-02-474833","article-title":"Recent progress toward epigenetic therapies: the example of mixed lineage","volume":"121","author":"Neff","year":"2013","journal-title":"Blood"},{"key":"2021050509375829000_b35-1440207","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/leu.2008.388","article-title":"AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features","volume":"23","author":"Haferlach","year":"2009","journal-title":"Leukemia"},{"key":"2021050509375829000_b36-1440207","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/bmt.2013.127","article-title":"Donor cell\u2013derived leukemia after cord blood transplantation and a review of the literature: differences between cord blood and BM as the transplant source","volume":"49","author":"Shiozaki","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"4, pt 2","key":"2021050509375829000_b37-1440207","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1055\/s-2006-942762","article-title":"Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia","volume":"32","author":"Kiladjian","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"2021050509375829000_b38-1440207","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1002\/cncr.21797","article-title":"t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy","volume":"106","author":"Yin","year":"2006","journal-title":"Cancer"},{"key":"2021050509375829000_b39-1440207","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ajh.21699","article-title":"Investigators of the multicenter study of hydroxyurea in sickle cell anemia and MSH patients\u2019 follow-up: the risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up","volume":"85","author":"Steinberg","year":"2010","journal-title":"Am J Hematol"},{"key":"2021050509375829000_b40-1440207","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/ajh.10427","article-title":"Malignancy in patients with sickle cell disease","volume":"74","author":"Schultz","year":"2003","journal-title":"Am J Hematol"},{"key":"2021050509375829000_b41-1440207","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2009-05-221333","article-title":"The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)","volume":"115","author":"Voskaridou","year":"2010","journal-title":"Blood"},{"key":"2021050509375829000_b42-1440207","first-page":"1","article-title":"Hydroxyurea for the treatment of sickle cell disease","volume":"165","author":"Segal","year":"2008","journal-title":"Evid Rep Technol"},{"key":"2021050509375829000_b43-1440207","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1002\/cncr.26537","article-title":"Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic\/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53","volume":"118","author":"Kanagal-Shamanna","year":"2012","journal-title":"Cancer"},{"key":"2021050509375829000_b44-1440207","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/leu.2013.133","article-title":"SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations","volume":"27","author":"Meggendorfer","year":"2013","journal-title":"Leukemia"},{"key":"2021050509375829000_b45-1440207","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ajh.23755","article-title":"Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10)","volume":"89","author":"Visconte","year":"2014","journal-title":"Am J Hematol"},{"key":"2021050509375829000_b46-1440207","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1200\/JCO.2011.38.7340","article-title":"Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms","volume":"30","author":"Nardi","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajcp\/article-pdf\/144\/2\/207\/37806776\/ajcpath144-0207.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajcp\/article-pdf\/144\/2\/207\/37806776\/ajcpath144-0207.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:54:12Z","timestamp":1717980852000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/144\/2\/207\/1766271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,1]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,8,1]]},"published-print":{"date-parts":[[2015,8,1]]}},"URL":"https:\/\/doi.org\/10.1309\/ajcpu1jo2lytwuav","relation":{},"ISSN":["1943-7722","0002-9173"],"issn-type":[{"value":"1943-7722","type":"electronic"},{"value":"0002-9173","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,8]]},"published":{"date-parts":[[2015,8,1]]}}}